A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis

Recruiting

Phase 3

BirtamimabA Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis

Sponsor:

Prothena Biosciences Ltd.

Code:

NCT04973137

Conditions

Light Chain (AL) Amyloidosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Birtamimab

Placebo

Standard of Care Chemotherapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Prothena Biosciences Ltd. on 2024-11-01.